Key facts
- Bionaut’s last known valuation is $123.3M.
- It has raised $83.0M; the latest was Later Stage VC ($12.9M) in May 2024.
- Notable investors include Alumni Ventures, Khosla Ventures, Gaingels, Calm Ventures, OurCrowd — 29 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for Bionaut
- ·The full record, as it builds
Funding rounds
No funding rounds for Bionaut are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bionaut
Developer of microscale robotic devices designed for targeted therapeutic delivery to specific areas affected by severe brain disorders. The company utilizes precision micro-technology to transport biologics or small-molecule therapies directly to localized disease sites, enabling medical professionals to achieve minimally invasive treatments, improve targeting accuracy, and potentially reduce side effects for patients requiring advanced neurological interventions.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2016
- Employees
- 41
- Website
- bionautlabs.com/
- Ownership
- Privately Held (backing)
Bionaut doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bionaut shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bionaut in its N-PORT filings yet. We sweep new filings monthly.